---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-009308"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T04:54:14.820365+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protalix appoints Gilad Mamlok as SVP & CFO effective Aug 24, 2025, succeeding Eyal Rubin

## Summary
- Gilad Mamlok appointed Senior VP & CFO, effective August 24, 2025.
- He succeeds Eyal Rubin, who resigned to pursue other opportunities.
- Mamlok brings 30 years experience, previously CFO of TytoCare and Sol-Gel Technologies.
- He receives monthly base salary of NIS 81,000 (~$24,066) plus discretionary bonus and options for 597,990 shares at $1.45.
- Options vest over 3 years, accelerated upon change of control.

## SEC filing metadata
- accession: 0001558370-25-009308
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837025009308/0001558370-25-009308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837025009308/plx-20250613x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-009308
- JSON: https://secwatch.observer/filing/0001558370-25-009308.json
- Plain text: https://secwatch.observer/filing/0001558370-25-009308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.